Ischenko I, D Amico S, Rao M, Li J, Hayman M, Powers S, et al. KRAS drives immune evasion in a genetic model of pancreatic cancer. Nat Commun. 2021;12:1482 pubmed publisher

Fotiadou P, Takahashi C, Rajabi H, Ewen M. Wild-type NRas and KRas perform distinct functions during transformation. Mol Cell Biol. 2007;27:6742-55 pubmed

Kasuga A, Semba T, Sato R, Nobusue H, Sugihara E, Takaishi H, et al. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice. Cancer Sci. 2021;112:1822-1838 pubmed publisher

Kennedy S, Jarboui M, Srihari S, Raso C, Bryan K, Dernayka L, et al. Extensive rewiring of the EGFR network in colorectal cancer cells expressing transforming levels of KRASG13D. Nat Commun. 2020;11:499 pubmed publisher

Kabayama H, Takeuchi M, Tokushige N, Muramatsu S, Kabayama M, Fukuda M, et al. An ultra-stable cytoplasmic antibody engineered for in vivo applications. Nat Commun. 2020;11:336 pubmed publisher

Ramírez C, Hauser A, Vucic E, Bar Sagi D. Plasma membrane V-ATPase controls oncogenic RAS-induced macropinocytosis. Nature. 2019;576:477-481 pubmed publisher

Bueno M, Jimenez Renard V, Samino S, Capellades J, Junza A, López Rodríguez M, et al. Essentiality of fatty acid synthase in the 2D to anchorage-independent growth transition in transforming cells. Nat Commun. 2019;10:5011 pubmed publisher

Yao W, Rose J, Wang W, Seth S, Jiang H, Taguchi A, et al. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature. 2019;: pubmed publisher

Lee S, Cho Y, Cha P, Yoon J, Ro E, Jeong W, et al. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab. Exp Mol Med. 2018;50:153 pubmed publisher

Ambrogio C, Köhler J, Zhou Z, Wang H, Paranal R, Li J, et al. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. Cell. 2018;172:857-868.e15 pubmed publisher

Waters A, Ozkan Dagliyan I, Vaseva A, Fer N, Strathern L, Hobbs G, et al. Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. Sci Signal. 2017;10: pubmed publisher

Chen X, Wu Q, Depeille P, Chen P, Thornton S, Kalirai H, et al. RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma. Cancer Cell. 2017;31:685-696.e6 pubmed publisher

Shen H, Xing C, Cui K, Li Y, Zhang J, Du R, et al. MicroRNA-30a attenuates mutant KRAS-driven colorectal tumorigenesis via direct suppression of ME1. Cell Death Differ. 2017;24:1253-1262 pubmed publisher

Taoka R, Jinesh G, Xue W, Safe S, Kamat A. CF3DODA-Me induces apoptosis, degrades Sp1, and blocks the transformation phase of the blebbishield emergency program. Apoptosis. 2017;22:719-729 pubmed publisher

Forzati F, De Martino M, Esposito F, Sepe R, Pellecchia S, Malapelle U, et al. miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene. BMC Cancer. 2017;17:170 pubmed publisher

Vallejo A, Perurena N, Guruceaga E, Mazur P, Martínez Canarias S, Zandueta C, et al. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. Nat Commun. 2017;8:14294 pubmed publisher

Dey K, Bharti R, Dey G, Pal I, Rajesh Y, Chavan S, et al. S100A7 has an oncogenic role in oral squamous cell carcinoma by activating p38/MAPK and RAB2A signaling pathway. Cancer Gene Ther. 2016;23:382-391 pubmed publisher

Jinesh G, Molina J, Huang L, Laing N, Mills G, Bar Eli M, et al. Mitochondrial oligomers boost glycolysis in cancer stem cells to facilitate blebbishield-mediated transformation after apoptosis. Cell Death Discov. 2016;2:16003 pubmed publisher

Li Y, Dillon T, Takahashi M, Earley K, Stork P. Protein Kinase A-independent Ras Protein Activation Cooperates with Rap1 Protein to Mediate Activation of the Extracellular Signal-regulated Kinases (ERK) by cAMP. J Biol Chem. 2016;291:21584-21595 pubmed

Weaver R, Limzerwala J, Naylor R, Jeganathan K, Baker D, van Deursen J. BubR1 alterations that reinforce mitotic surveillance act against aneuploidy and cancer. elife. 2016;5: pubmed publisher

Anta B, Pérez Rodríguez A, Castro J, García Domínguez C, Ibiza S, Martínez N, et al. PGA1-induced apoptosis involves specific activation of H-Ras and N-Ras in cellular endomembranes. Cell Death Dis. 2016;7:e2311 pubmed publisher

Petrova L, Gran C, Bjoras M, Doetsch P. Efficient and Reliable Production of Vectors for the Study of the Repair, Mutagenesis, and Phenotypic Consequences of Defined DNA Damage Lesions in Mammalian Cells. PLoS ONE. 2016;11:e0158581 pubmed publisher

Pereira D, Simões A, Gomes S, Castro R, Carvalho T, Rodrigues C, et al. MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism. Oncotarget. 2016;7:34322-40 pubmed publisher

Tsang Y, Dogruluk T, Tedeschi P, Wardwell Ozgo J, Lu H, Espitia M, et al. Functional annotation of rare gene aberration drivers of pancreatic cancer. Nat Commun. 2016;7:10500 pubmed publisher

Chung S, Moon H, Ju H, Kim D, Cho K, Ribback S, et al. Comparison of liver oncogenic potential among human RAS isoforms. Oncotarget. 2016;7:7354-66 pubmed publisher

Chen Y, Zheng Y, You X, Yu M, Fu G, Su X, et al. Kras Is Critical for B Cell Lymphopoiesis. J Immunol. 2016;196:1678-85 pubmed publisher

Kim J, Sato M, Choi J, Kim H, Yeh B, Larsen J, et al. Nuclear Receptor Expression and Function in Human Lung Cancer Pathogenesis. PLoS ONE. 2015;10:e0134842 pubmed publisher

Brito H, Martins A, Lavrado J, Mendes E, Francisco A, Santos S, et al. Targeting KRAS Oncogene in Colon Cancer Cells with 7-Carboxylate Indolo[3,2-b]quinoline Tri-Alkylamine Derivatives. PLoS ONE. 2015;10:e0126891 pubmed publisher

Huang L, Counter C. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S. PLoS ONE. 2015;10:e0123918 pubmed publisher

Hu S, Danilov A, Godek K, Orr B, Tafe L, Rodriguez Canales J, et al. CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110. Cancer Res. 2015;75:2029-38 pubmed publisher

Stolze B, Reinhart S, Bulllinger L, Fröhling S, Scholl C. Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines. Sci Rep. 2015;5:8535 pubmed publisher

Gao J, Du J, Wang Y, Li J, Wei L, Guo M. Synergistic effects of curcumin and bevacizumab on cell signaling pathways in hepatocellular carcinoma. Oncol Lett. 2015;9:295-299 pubmed

Huang L, Carney J, Cardona D, Counter C. Decreased tumorigenesis in mice with a Kras point mutation at C118. Nat Commun. 2014;5:5410 pubmed publisher

Fujimura K, Wright T, Strnadel J, Kaushal S, Metildi C, Lowy A, et al. A hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancer. Cancer Res. 2014;74:6671-81 pubmed publisher

Song J, An N, Chatterjee S, Kistner Griffin E, Mahajan S, Mehrotra S, et al. Deletion of Pim kinases elevates the cellular levels of reactive oxygen species and sensitizes to K-Ras-induced cell killing. Oncogene. 2015;34:3728-36 pubmed publisher

Patel A, Burton D, Halvorsen K, Balkan W, Reiner T, Perez Stable C, et al. MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways. Oncogene. 2015;34:2586-96 pubmed publisher

Bauckman K, Haller E, Flores I, Nanjundan M. Iron modulates cell survival in a Ras- and MAPK-dependent manner in ovarian cells. Cell Death Dis. 2013;4:e592 pubmed publisher

BENTLEY C, Jurinka S, Kljavin N, Vartanian S, Ramani S, Gonzalez L, et al. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation. Biochem J. 2013;452:313-20 pubmed publisher

Vartanian S, BENTLEY C, Brauer M, Li L, Shirasawa S, Sasazuki T, et al. Identification of mutant K-Ras-dependent phenotypes using a panel of isogenic cell lines. J Biol Chem. 2013;288:2403-13 pubmed publisher

Neu J, Dziunycz P, Dzung A, Lefort K, Falke M, Denzler R, et al. miR-181a decelerates proliferation in cutaneous squamous cell carcinoma by targeting the proto-oncogene KRAS. PLoS ONE. 2017;12:e0185028 pubmed publisher

Takahashi M, Li Y, Dillon T, Kariya Y, Stork P. Phosphorylation of the C-Raf N Region Promotes Raf Dimerization. Mol Cell Biol. 2017;37: pubmed publisher

Sun T, Liu S, Zhou Y, Yao Z, Zhang D, Cao S, et al. Evolutionary biologic changes of gut microbiota in an 'adenoma-carcinoma sequence' mouse colorectal cancer model induced by 1, 2-Dimethylhydrazine. Oncotarget. 2017;8:444-457 pubmed publisher

Shimizu K, Kobayashi Y, Nakatsuji E, Yamazaki M, Shimba S, Sakimura K, et al. SCOP/PHLPP1? mediates circadian regulation of long-term recognition memory. Nat Commun. 2016;7:12926 pubmed publisher

Caiola E, Brunelli L, Marabese M, Broggini M, Lupi M, Pastorelli R. Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS. Oncotarget. 2016;7:51462-51472 pubmed publisher

Klein K, Werner K, Teske C, Schenk M, Giese T, Weitz J, et al. Role of TFEB-driven autophagy regulation in pancreatic cancer treatment. Int J Oncol. 2016;49:164-72 pubmed publisher

Song C, Liu L, Pei X, Liu X, Yang L, Ye F, et al. miR-200c inhibits breast cancer proliferation by targeting KRAS. Oncotarget. 2015;6:34968-78 pubmed publisher

Unni A, Lockwood W, Zejnullahu K, Lee Lin S, Varmus H. Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. elife. 2015;4:e06907 pubmed publisher

Jin X, Sun Y, Yang H, Li J, Yu S, Chang X, et al. Deregulation of the MiR-193b-KRAS Axis Contributes to Impaired Cell Growth in Pancreatic Cancer. PLoS ONE. 2015;10:e0125515 pubmed publisher

Ju H, Calvisi D, Moon H, Baek S, Ribback S, Dombrowski F, et al. Transgenic mouse model expressing P53(R172H), luciferase, EGFP, and KRAS(G12D) in a single open reading frame for live imaging of tumor. Sci Rep. 2015;5:8053 pubmed publisher

Sun Y, Chen C, Zhang P, Xie H, Hou L, Hui Z, et al. Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway. Sci Rep. 2014;4:6527 pubmed publisher

Qi X, Xie C, Hou S, Li G, Yin N, Dong L, et al. Identification of a ternary protein-complex as a therapeutic target for K-Ras-dependent colon cancer. Oncotarget. 2014;5:4269-82 pubmed

Okada M, Shibuya K, Sato A, Seino S, Suzuki S, Seino M, et al. Targeting the K-Ras--JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation. Oncotarget. 2014;5:5100-12 pubmed

Shukla S, Allam U, Ahsan A, Chen G, Krishnamurthy P, Marsh K, et al. KRAS protein stability is regulated through SMURF2: UBCH5 complex-mediated β-TrCP1 degradation. Neoplasia. 2014;16:115-28 pubmed publisher

Ceccarelli V, Nocentini G, Billi M, Racanicchi S, Riccardi C, Roberti R, et al. Eicosapentaenoic acid activates RAS/ERK/C/EBP? pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. PLoS ONE. 2014;9:e85025 pubmed publisher

Le Floc h A, Tanaka Y, Bantilan N, Voisinne G, Altan Bonnet G, Fukui Y, et al. Annular PIP3 accumulation controls actin architecture and modulates cytotoxicity at the immunological synapse. J Exp Med. 2013;210:2721-37 pubmed publisher

Azrak S, Ginel Picardo A, Drosten M, Barbacid M, Santos E. Reversible, interrelated mRNA and miRNA expression patterns in the transcriptome of Rasless fibroblasts: functional and mechanistic implications. BMC Genomics. 2013;14:731 pubmed publisher

Johnson J, de Mejia E. Flavonoid apigenin modified gene expression associated with inflammation and cancer and induced apoptosis in human pancreatic cancer cells through inhibition of GSK-3?/NF-?B signaling cascade. Mol Nutr Food Res. 2013;57:2112-27 pubmed publisher

Commisso C, Davidson S, Soydaner Azeloglu R, Parker S, Kamphorst J, Hackett S, et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature. 2013;497:633-7 pubmed publisher

Son J, Lyssiotis C, Ying H, Wang X, Hua S, Ligorio M, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013;496:101-5 pubmed publisher

Valtorta E, Misale S, Sartore Bianchi A, Nagtegaal I, Paraf F, Lauricella C, et al. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int J Cancer. 2013;133:1259-65 pubmed publisher

Huang H, Daniluk J, Liu Y, Chu J, Li Z, Ji B, et al. Oncogenic K-Ras requires activation for enhanced activity. Oncogene. 2014;33:532-5 pubmed publisher

Ma Y, Gu Y, Zhang Q, Han Y, Yu S, Lu Z, et al. Targeted degradation of KRAS by an engineered ubiquitin ligase suppresses pancreatic cancer cell growth in vitro and in vivo. Mol Cancer Ther. 2013;12:286-94 pubmed publisher

Shao D, Tsherniak A, Gopal S, Weir B, Tamayo P, Stransky N, et al. ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res. 2013;23:665-78 pubmed publisher

Wang Y, Ren T, Cai Y, He X. MicroRNA let-7a inhibits the proliferation and invasion of nonsmall cell lung cancer cell line 95D by regulating K-Ras and HMGA2 gene expression. Cancer Biother Radiopharm. 2013;28:131-7 pubmed publisher

Hofmann I, Weiss A, Elain G, Schwaederle M, Sterker D, Romanet V, et al. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. PLoS ONE. 2012;7:e44146 pubmed publisher

Li C, Ge M, Yin Y, Luo M, Chen D. Silencing expression of ribosomal protein L26 and L29 by RNA interfering inhibits proliferation of human pancreatic cancer PANC-1 cells. Mol Cell Biochem. 2012;370:127-39 pubmed publisher

Ikonomou G, Kostourou V, Shirasawa S, Sasazuki T, Samiotaki M, Panayotou G. Interplay between oncogenic K-Ras and wild-type H-Ras in Caco2 cell transformation. J Proteomics. 2012;75:5356-69 pubmed publisher

Kent O, Fox Talbot K, Halushka M. RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets. Oncogene. 2013;32:2576-85 pubmed publisher

Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532-6 pubmed publisher

Ferreira L, Fuentes Calvo I, Muñoz Félix J, Muñiz Martín C, Sánchez Juanes F, Raposo C, et al. Functional specific roles of H-ras and N-ras. A proteomic approach using knockout cell lines. Electrophoresis. 2012;33:1385-96 pubmed publisher

Linley A, Mathieu M, Miles A, Rees R, McArdle S, Regad T. The helicase HAGE expressed by malignant melanoma-initiating cells is required for tumor cell proliferation in vivo. J Biol Chem. 2012;287:13633-43 pubmed publisher

Jiao L, Frampton A, Jacob J, Pellegrino L, Krell J, Giamas G, et al. MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. PLoS ONE. 2012;7:e32068 pubmed publisher

Colmegna I, Pryshchep S, Oishi H, Goronzy J, Weyand C. Dampened ERK signaling in hematopoietic progenitor cells in rheumatoid arthritis. Clin Immunol. 2012;143:73-82 pubmed publisher

Rak Mardyła A, Gregoraszczuk E, Karpeta A, Duda M. Expression of ghrelin and the ghrelin receptor in different stages of porcine corpus luteum development and the inhibitory effects of ghrelin on progesterone secretion, 3?-hydroxysteroid dehydrogenase (3?-honestly significant difference (HSD)) activi. Theriogenology. 2012;77:1505-12 pubmed publisher

Kim C, Vo M, Kim H, Lee H, Yoon N, Lee B, et al. Ectopic over-expression of tristetraprolin in human cancer cells promotes biogenesis of let-7 by down-regulation of Lin28. Nucleic Acids Res. 2012;40:3856-69 pubmed publisher

Kosaka N, Iguchi H, Yoshioka Y, Hagiwara K, Takeshita F, Ochiya T. Competitive interactions of cancer cells and normal cells via secretory microRNAs. J Biol Chem. 2012;287:1397-405 pubmed publisher

Acin S, Li Z, Mejía O, Roop D, El Naggar A, Caulin C. Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras. J Pathol. 2011;225:479-89 pubmed publisher

Dhurandhar E, Dubuisson O, Mashtalir N, Krishnapuram R, Hegde V, Dhurandhar N. E4orf1: a novel ligand that improves glucose disposal in cell culture. PLoS ONE. 2011;6:e23394 pubmed publisher

Yeh C, Lin K, Chen T, Wu R, Tsao L, Chen Y, et al. Characterization of a novel rat cholangiocarcinoma cell culture model-CGCCA. World J Gastroenterol. 2011;17:2924-32 pubmed publisher

Peng S, Chen L, Lei X, Yang L, Lin H, Carmichael G, et al. Genome-wide studies reveal that Lin28 enhances the translation of genes important for growth and survival of human embryonic stem cells. Stem Cells. 2011;29:496-504 pubmed publisher

Jung Y, Lee S, Choi H, Kim S, Lee E, Shin Y, et al. Clinical validation of colorectal cancer biomarkers identified from bioinformatics analysis of public expression data. Clin Cancer Res. 2011;17:700-9 pubmed publisher

Huang J, Wang F, Okuka M, Liu N, Ji G, Ye X, et al. Association of telomere length with authentic pluripotency of ES/iPS cells. Cell Res. 2011;21:779-92 pubmed publisher

López Vicente L, Pons B, Coch L, Teixidó C, Hernandez Losa J, Armengol G, et al. RSK4 inhibition results in bypass of stress-induced and oncogene-induced senescence. Carcinogenesis. 2011;32:470-6 pubmed publisher

Steinbrunn T, Stühmer T, Gattenlohner S, Rosenwald A, Mottok A, Unzicker C, et al. Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. Blood. 2011;117:1998-2004 pubmed publisher

Majumdar A, Ghosh A, Datta S, Prudner B, Datta B. p67/MetAP2 suppresses K-RasV12-mediated transformation of NIH3T3 mouse fibroblasts in culture and in athymic mice. Biochemistry. 2010;49:10146-57 pubmed publisher

Ramsingh G, Koboldt D, Trissal M, Chiappinelli K, Wylie T, Koul S, et al. Complete characterization of the microRNAome in a patient with acute myeloid leukemia. Blood. 2010;116:5316-26 pubmed publisher

Alvarez Moya B, López Alcalá C, Drosten M, Bachs O, Agell N. K-Ras4B phosphorylation at Ser181 is inhibited by calmodulin and modulates K-Ras activity and function. Oncogene. 2010;29:5911-22 pubmed publisher

Kreeger P, Wang Y, Haigis K, Lauffenburger D. Integration of multiple signaling pathway activities resolves K-RAS/N-RAS mutation paradox in colon epithelial cell response to inflammatory cytokine stimulation. Integr Biol (Camb). 2010;2:202-8 pubmed publisher

Vignola M, Kashatus D, Taylor G, Counter C, Valdivia R. cPLA2 regulates the expression of type I interferons and intracellular immunity to Chlamydia trachomatis. J Biol Chem. 2010;285:21625-35 pubmed publisher

Vidic S, Markelc B, Sersa G, Coer A, Kamensek U, Tevz G, et al. MicroRNAs targeting mutant K-ras by electrotransfer inhibit human colorectal adenocarcinoma cell growth in vitro and in vivo. Cancer Gene Ther. 2010;17:409-19 pubmed publisher

Fuentes Calvo I, Blázquez Medela A, Santos E, Lopez Novoa J, Martinez Salgado C. Analysis of k-ras nuclear expression in fibroblasts and mesangial cells. PLoS ONE. 2010;5:e8703 pubmed publisher

Barbie D, Tamayo P, Boehm J, Kim S, Moody S, Dunn I, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462:108-12 pubmed publisher

Suzuki H, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature. 2009;460:529-33 pubmed publisher

Mita H, Toyota M, Aoki F, Akashi H, Maruyama R, Sasaki Y, et al. A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth. BMC Cancer. 2009;9:198 pubmed publisher

Viswanathan S, Powers J, Einhorn W, Hoshida Y, Ng T, Toffanin S, et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009;41:843-8 pubmed publisher

Sasaki R, Narisawa Saito M, Yugawa T, Fujita M, Tashiro H, Katabuchi H, et al. Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes. Carcinogenesis. 2009;30:423-31 pubmed publisher

Kong D, Song S, Kim D, Joo K, Yoo J, Koh J, et al. Prognostic significance of c-Met expression in glioblastomas. Cancer. 2009;115:140-8 pubmed publisher

Kim S, Lee Y, Kim Y, Bahk Y. A Proteomic approach for protein-profiling the oncogenic ras induced transformation (H-, K-, and N-Ras) in NIH/3T3 mouse embryonic fibroblasts. Proteomics. 2008;8:3082-93 pubmed publisher

Hao J, Wang G, Pisitkun T, Patino Lopez G, Nagashima K, Knepper M, et al. Enrichment of distinct microfilament-associated and GTP-binding-proteins in membrane/microvilli fractions from lymphoid cells. J Proteome Res. 2008;7:2911-27 pubmed publisher

Nakajima J, Ishikawa S, Hamada J, Yanagihara M, Koike T, Hatakeyama M. Anti-tumor activity of ESX1 on cancer cells harboring oncogenic K-ras mutation. Biochem Biophys Res Commun. 2008;370:189-94 pubmed publisher

Podsypanina K, Politi K, Beverly L, Varmus H. Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras. Proc Natl Acad Sci U S A. 2008;105:5242-7 pubmed publisher

Turner S, Zhuang S, Zhang T, Boss G, Pilz R. Effects of lovastatin on Rho isoform expression, activity, and association with guanine nucleotide dissociation inhibitors. Biochem Pharmacol. 2008;75:405-13 pubmed

Pandey J, Umphress S, Kang Y, Angdisen J, Naumova A, Mercer K, et al. Modulation of tumor induction and progression of oncogenic K-ras-positive tumors in the presence of TGF- b1 haploinsufficiency. Carcinogenesis. 2007;28:2589-96 pubmed

Li H, Cao H, Wan J, Li Y, Zhu M, Zhao P. Growth inhibitory effect of wild-type Kras2 gene on a colonic adenocarcinoma cell line. World J Gastroenterol. 2007;13:934-8 pubmed

Lutterbach B, Zeng Q, Davis L, Hatch H, Hang G, Kohl N, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 2007;67:2081-8 pubmed

Uchida A, Hirano S, Kitao H, Ogino A, Rai K, Toyooka S, et al. Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. Cancer Sci. 2007;98:357-63 pubmed

Psahoulia F, Moumtzi S, Roberts M, Sasazuki T, Shirasawa S, Pintzas A. Quercetin mediates preferential degradation of oncogenic Ras and causes autophagy in Ha-RAS-transformed human colon cells. Carcinogenesis. 2007;28:1021-31 pubmed

Keller J, Franklin J, Graves Deal R, Friedman D, Whitwell C, Coffey R. Oncogenic KRAS provides a uniquely powerful and variable oncogenic contribution among RAS family members in the colonic epithelium. J Cell Physiol. 2007;210:740-9 pubmed

Keller J, Haigis K, Franklin J, Whitehead R, Jacks T, Coffey R. Oncogenic K-RAS subverts the antiapoptotic role of N-RAS and alters modulation of the N-RAS:gelsolin complex. Oncogene. 2007;26:3051-9 pubmed

Ehmann F, Horn S, Garcia Palma L, Wegner W, Fiedler W, Giehl K, et al. Detection of N-RAS and K-RAS in their active GTP-bound form in acute myeloid leukemia without activating RAS mutations. Leuk Lymphoma. 2006;47:1387-91 pubmed

Xiang S, Fruehauf J, Li C. Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. Nat Biotechnol. 2006;24:697-702 pubmed

Forlani G, Baldassa S, Lavagni P, Sturani E, Zippel R. The guanine nucleotide exchange factor RasGRF1 directly binds microtubules via DHPH2-mediated interaction. FEBS J. 2006;273:2127-38 pubmed

Liu J, Xie Y, Merrick B, Shen J, Ducharme D, Collins J, et al. Transplacental arsenic plus postnatal 12-O-teradecanoyl phorbol-13-acetate exposures associated with hepatocarcinogenesis induce similar aberrant gene expression patterns in male and female mouse liver. Toxicol Appl Pharmacol. 2006;213:216-23 pubmed

Mattingly R, Kraniak J, Dilworth J, Mathieu P, Bealmear B, Nowak J, et al. The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines. J Pharmacol Exp Ther. 2006;316:456-65 pubmed

Roberts M, Drosopoulos K, Vasileiou I, Stricker M, Taoufik E, Maercker C, et al. Microarray analysis of the differential transformation mediated by Kirsten and Harvey Ras oncogenes in a human colorectal adenocarcinoma cell line. Int J Cancer. 2006;118:616-27 pubmed

Fleming J, Shen G, Holloway S, Davis M, Brekken R. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol Cancer Res. 2005;3:413-23 pubmed

Wang Y, Van Becelaere K, Jiang P, Przybranowski S, Omer C, Sebolt Leopold J. A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. Neoplasia. 2005;7:336-47 pubmed

Boivin B, Villeneuve L, Farhat N, Chevalier D, Allen B. Sub-cellular distribution of endothelin signaling pathway components in ventricular myocytes and heart: lack of preformed caveolar signalosomes. J Mol Cell Cardiol. 2005;38:665-76 pubmed

Oh Hora M, Johmura S, Hashimoto A, Hikida M, Kurosaki T. Requirement for Ras guanine nucleotide releasing protein 3 in coupling phospholipase C-gamma2 to Ras in B cell receptor signaling. J Exp Med. 2003;198:1841-51 pubmed